Evaluation of the (P-SOFT) Score as a Novel Method to Predict Patient Survival following Living Donor Liver Transplantation in Egypt

Thesis

Submitted for partial fulfillment of master degree in **Internal medicine**

Presented by

Mohamed Khalil Ibrahim M.B.B.CH

Under supervision of

Prof. Dr. Mahmoud Abd El Megid Osman

Professor of internal medicine, hepatology and GIT Faculty of Medicine
Ain Shams University

Prof. Dr. Mahmoud Shawqy El Meteini

Professor of general surgery and liver transplantation Faculty of Medicine Ain Shams University

Prof. Dr. Mohamed Fathy Abd El Ghaffar

Professor of general surgery and liver transplantation Faculty of Medicine Ain Shams University

> Faculty of Medicine Ain Shams University 2014

<u>Acknowledgement</u>

To **Allah** the all knowing, whose knowledge is beyond all the knowledge and to Him I relate any success in my life.

I am honored to have **Prof. Dr. Mahmoud Abd El Megíd Osman,** Prof. of internal medicine and hepatology, Faculty of Medicine, Ain Shams University, as a supervisor of this work. I am so grateful and most appreciative to his efforts.

I am deeply thankful to **Prof. Dr. Mahmoud Shawqy El Meteini,** Prof. of general surgery and liver transplantation, Faculty of Medicine, Ain Shams University, not only for his great help and effort to make this work possible, but also for his patience and valuable advices.

I would like to thank **Prof. Dr. Mohamed Fathy Abd El Ghaffar**, Prof. of general surgery and liver transplantation, Faculty of Medicine, Ain Shams University, for his valuable and helpful support and for his kind co-operation.

My special deep thanks and iam so grateful to **Dr. Sameh Abd El Bary**, Lecturer of internal medicine and hepatology, Faculty of Medicine, Ain Shams University, for his kind co-operation and being beside me step by step like a brother allthrough this work.

My gratitude extends to my colleagues in the Armed Forces hospitals for their continous support and encouragement wih special appreciation for **General Dr. Magdi Amin Mubarak**, Prof. of general surgery and liver transplantation and the head of Maadi military center of Liver Transplantation for his support and fruitful help.

I would like to thank **Prof. Dr. Magdy Ibrahim**, Research & Biostatistics Unit, MEDC, Cairo University who has taught me a great deal about statistical analysis.

I have never forgotten my kind **family**; father, mother, brothers and sisters .No words can make a dedication to match what they deserve.

Most notably, I am deeply thankful and grateful for the love of my small family; my wife and daughter, who have always been unwavering in their support. Even on my down days, they always make me feel as though I deserve the Nobel Prize.

Mohamed Khalil

2014

Contents

Title	Page
Acknowledgement	i
List of contents	iii
List of Figures	iv
List of tables	V
List of abbreviations	vi
Introduction	1
Aim of the study	2
Review of literature:	
Chapter One: Anatomy of the Liver	3
Chapter Two: Liver Cirrhosis	11
Chapter Three: Pretransplant	
management of	23
complications of liver	
cirrhosis	
Chapter Four: Liver	51
Transplanation	
Chapter Five: Outcomes post	79
liver transplantation	
Chapter six: Predicting patient	87
survival post LDLT	
Patients and Methods	92
Results	97
Discussion	107
Conclusion & Recommendation	114
Summary	116
References	119
Arabic Summary	I

List of Figures

Figure No.	Title	PageNo.
Fig. (1)	Posterior view of the liver	3
Fig. (2)	The Couinaud segments and	5
	their corresponding	
	traditional nomenclature	
Fig. (3)	Microscopic anatomy of the	6
	liver	
Fig. (4)	Diagram of the functional	7
	segments using the	
	nomenclature of Couinaud	
Fig. (5)	Gross and microscopic images	12
	of a normal and cirrhotic liver	
Fig. (6)	The 10 Leading Causes of	13
	Death in Adults	
Fig. (7)	Diagram of the portal	25
	circulation	
Fig. (8)	Management algorithm for	28
	primary prophylaxis of	
	variceal hemorrhage	
Fig. (9)	Management algorithm for	30
	acute variceal hemorrhage	
Fig. (10)	Peritoneovenous shunt	36
Fig. (11)	Pathogenesis of type 1 and	41
	type 2 HRS	
Fig. (12)	Risk factors of primary liver	62
	cancer and estimated	
	attributable fractions in	
	different parts of the world	
Fig. (13)	Percentage of survival and	97
	mortality in the studied	
	patients	
Fig. (14)	The P-SOFT Score	98
	Distribution Frequency	
Fig. (15)	Percentage of patients	98
	according to different risk	
	groups	
Fig. (16)	Survival and mortality among	100
	different risk groups	
Fig. (17)	Kaplan–Meier curve of	101
	survival by P-SOFT score	

Table of figures

Fig. (18)	Mean and median of survival	102
	times between different risk	
	groups	
Fig. (19)	mean and median readings of	103
	survived, died and total	
	patients	
Fig. (20)	The Roc curve	103
Fig. (21)	Survival according to gender	106

List of Tables

Table No.	Title	PageNo.
Tab. (1)	Complications of Cirrhosis	23
Tab. (2)	Classification of ascites	34
	according to severity,	
	complication, and response to	
	diuretic treatment	
Tab. (3)	Precipitants of acute hepatic	42
	encephalopathy in the	
	cirrhotic patient	
Tab. (4)	The stages of hepatic	43
	encephalopathy as well as	
	their respective	
	symptomatology	
Tab. (5)	Child-Turcotte-Pugh scoring	50
	system to assess liver disease	
	severity	
Tab. (6)	Indications for Liver	53
	transplantation	
Tab. (7)	Clinical spectrum of Wilson's	68
	disease	
Tab. (8)	King's College Criteria for	70
	Liver Transplantation in	
	Fulminant Liver Failure	
Tab. (9)	Absolute contraindications to	72
	liver transplantation	
Tab. (10)	Model for End-Stage Liver	78
	Disease Score	
Tab. (11)	Allograft dysfunction and	80
	surgical complications	
	occurring in the immediate	
m 1 ()	postoperative period	•
Tab. (12)	Biliary complications	83
Tab. (13)	Medical complications	84
	occurring in the immediate	
m-1. (4.4)	postoperative period	0-
Tab. (14)	Signs of primary liver graft	85
Tob (4-)	nonfunction The P. COET george	
Tab. (15)	The P-SOFT score	92
Tab. (16)	Recipient mortality odds and	99
	odds ratio based on the low	

List of Tables

	risk group	
Tab. (17)	Patients distribution	99
	according to survival and	
	mortality among different risk	
	groups	
Tab. (18)	Mean and median of survival	101
	times between different risk	
	groups	
Tab. (19)	The P-SOFT score and over-	102
	all survival statistics (for died,	
	survived and total)	
Tab. (20)	Summary of recipient risk	104
	factors analysis	
Tab. (21)	Sex * Survival	105

List of Abbreviations


Title	Abbreviation
AASLD	American Association for the Study of Liver Diseases
A2ALL	Adult-to-Adult Living Donor Liver Transplantation
ACE	Angiotensin-converting Enzyme
ADH	Antidiuretic hormone
ACLF	Acute-on-chronic liver failure
AIDS	Acquired Immune Deficiency Syndrome
ALT	Alanine transaminase
AMA	Antimitochondrial antibodies
AFP	Alpha fetoprotein
a-SMA	Smooth muscle a-actin
AST	Aspartate transaminase
ATN	Acute tubular necrosis
ATP	Adenosine triphosphate
BD	Bile duct
B.I.D	Bis in die= Twice a day
BMI	Body mass index
CAD	Coronary artery disease
CEA	Carcinoembryonic antigen
CI	Confidence Interval
CMV	Cytomegalovirus
COPD	Chronic Obstructive Pulmonary Disease
CTP	Child-Turcotte-Pugh score
CV	Central vein
DDLT	Deceased donor liver transplantation
DM	Diabetes Mellitus
ECM	Extracellular matrix
EEG	Electroencephalography
EGD	Esophagogastroduodenoscopy
ESLD	End-stage liver disease
EVL	Endoscopic variceal ligation
FHVP	Free hepatic venous pressure
GGTP	Gamma glutamyltranspeptidase
GFR	Glomerular Filtration Rate
GGT	Gamma-glutamyl transpeptidase
HAT	Hepatic artery thrombosis
HBIg	Hepatitis B Immune Globulin
HBV	Hepatitis B virus
HCC	Hepatocellular carcinoma

List of abbreviations

HCV	Hepatitis C virus
HE	Hepatic encephalopathy
HIV	Human Immunodeficiency Virus
HM	Hepatic myofibroblasts
HPS	Hepatopulmonary syndrome
HR	Hazard ratio
HRS	Hepatorenal Syndrome
HSCs	Hepatic Stellate Cells
HVPG	Hepatic venous pressure gradient
ICU	Intensive care unit
IHD	Ischemic Heart Disease
INR	International normalized ratio
IQ	Intelligence quotient
I.V	Intravenous
LDLT	Living-donor liver transplantation
LT	Liver transplantation
MELD	Model for End-Stage Liver Disease
MMPs	Matrix metalloproteinases
NAFLD	Non-Alcoholic Fatty Liver Disease
NASH	nonalcoholic steatohepatitis
NO	Nitric oxide
NSAIDs	Non-Steroidal Anti-Inflammatory Drugs
OAS	Over all survival
PAP smear	Papanicolaou smear
PBC	Primary Biliary Cirrhosis
PFT	Pulmonary function test
PHG	Portal hypertensive gastropathy
PSC	Primary Sclerosing Cholangitis
P-SOFT	Preallocation score to predict Survival Outcomes
	Following Liver Transplantation
PT	Prothrombin time
PTH	Parathyroid hormone
PTT	Partial Thromboplastin Time
PV	Portal vein
PVT	Portal vein thrombosis
RPF	Renal plasma flow
RAAS	Renin-angiotensin-aldosterone system
ROC	Receiver Operator Characteristic
SAAG	Serum–ascites albumin gradient
SBP	Spontaneous bacterial peritonitis
SD	Standard Deviation
SNS	Sympathetic Nervous System

List of abbreviations

SPECT	Single-photon emission computed tomography
SPSS	Statistical Package for the Social Science
SVR	Sustained viral response
TB	Tuberculosis
TGF-β1	Transforming growth factor-beta 1
T.I.D	Ter in die= Thrice a day
TIMP-1	Tissue inhibitor of metalloproteinase-1
TIPS	Transjugular Intrahepatic Portosystemic Shunt
UNOS	United Network for Organ Sharing
VEP	Visual evoked potential
WD	Wilson's disease
WHVP	Wedged hepatic venous pressure



Introduction

Cirrhosis of liver is a common health problem and results in significant morbidity and mortality. In the past, treatment of cirrhosis was mostly supportive and directed toward management of complications of this disease. Liver transplantation has changed the management and outcome of patients with cirrhosis of liver (*Perkins*, 2006).

All patients with end-stage cirrhosis should be considered for liver transplantation in good time and for many patients in a life-threatening situation, liver transplantation remains the only chance for survival (*Kuntz*, 2006).


Living-donor liver transplantation (LDLT) has been refined and accepted as a valuable treatment for patients with end-stage liver disease in order to overcome the shortage of organs and mortality on the waiting list (*Imura et al, 2008*).

The Model for End-Stage Liver Disease (MELD) score is an independent predictor of mortality in patients with cirrhosis and those who are awaiting liver transplantation. The MELD score has been proven to be an accurate predictor of waitlist mortality, as demonstrated in the pioneering study by Wiesner et al., with a c-statistic of 0.83 when used to predict 3-month mortality of candidates on the waitlist (*Wiesner et al*, 2003).

However, the MELD score is a poor predictor of mortality following transplantation. This observation was confirmed by Desai et al. in their analysis, which reports a c-statistic of only 0.54 with the use of the MELD to predict 3-month recipient mortality following liver transplantation (*Desai et al, 2004*).

Methods other than the MELD score, such as the Child-Turcotte-Pugh score, also had a poor ability to predict post transplant survival (*Brown et al*, 2002).

The Preallocation score to predict Survival Outcomes Following Liver Transplantation (P-SOFT) was designed to accurately predict the waitlist mortality with a c-statistic of 0.69 as a predictor of 3-month recipient survival following liver transplantation (*Rana et al.*, 2008).



Aim of the work

The aim of our work is to highlight the P-SOFT score and to assess its ability to predict the recipient survival at 3 months following living donor liver transplantation in Egypt.